Predictive Value of aEEG and Cerebral Oxygenation on Neurological Outcomes in Newborns With Mild Hypoxic-Ischemic Encephalopathy

April 27, 2026 updated by: Salih Çağrı Çakır, Uludag University

Predictive Value of Amplitude-Integrated Electroencephalography and Cerebral Tissue Oxygenation on Neurological Outcomes in Neonates With Mild Hypoxic-Ischemic Encephalopathy

Newborns with mild hypoxic-ischemic encephalopathy usually do not receive cooling treatment. However, some of these newborns may develop neurological problems later in life. This observational study aims to evaluate whether early brain monitoring and measurements of brain oxygen levels are associated with neurological outcomes in newborns with mild hypoxic-ischemic encephalopathy. Newborns will be monitored during the first 72 hours after birth as part of routine clinical care. Neurological assessments will be performed during early infancy and later follow-up. The findings of this study may help improve early risk assessment and support closer monitoring of newborns who may be at increased risk for unfavorable neurological outcomes.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Perinatal asphyxia resulting from impaired gas exchange may lead to hypoxemia, hypercapnia, and metabolic acidosis, causing injury to the brain and other organs in newborns. Perinatal asphyxia disrupts cerebral autoregulation, leading to primary and secondary energy deficiency, cerebral damage, and hypoxic-ischemic encephalopathy (HIE). HIE remains a significant cause of neonatal mortality and long-term neurological morbidity. HIE is clinically classified as mild, moderate, or severe based on neurological examination findings, most commonly using the Sarnat and Sarnat scoring system. Therapeutic hypothermia has been shown to reduce mortality and morbidity in term and near-term newborns with moderate to severe HIE when initiated within the first 6 hours after birth. However, therapeutic hypothermia is not routinely recommended for newborns with mild HIE due to the lack of sufficient evidence from randomized clinical trials. Although mild HIE is generally associated with a better prognosis, accumulating evidence suggests that a substantial proportion of newborns diagnosed with mild HIE may develop adverse neurodevelopmental outcomes during infancy and early childhood.

Furthermore, the severity of encephalopathy may evolve, and some newborns initially classified as having mild HIE may progress to moderate encephalopathy within the first hours after birth. Early identification of newborns with mild HIE who are at increased risk for neurological deterioration remains challenging, particularly during the critical first 6 hours of life. Continuous bedside brain monitoring techniques may provide valuable prognostic information in this early period. Amplitude-integrated electroencephalography (aEEG) allows continuous assessment of cerebral electrical activity. It helps evaluate the severity of encephalopathy, detect seizures, and predict neurological outcomes in newborns with HIE. Additionally, near-infrared spectroscopy (NIRS) allows for non-invasive monitoring of cerebral oxygenation and cerebral fractional tissue oxygen extraction (cFTOE). However, data regarding the use of NIRS in newborns with mild HIE are limited, particularly during the early postnatal period.

The primary objective of this prospective, multicenter observational cohort study is to investigate the association between early brain monitoring findings and short-term and long-term neurological outcomes in newborns with mild hypoxic-ischemic encephalopathy. Specifically, the study aims to evaluate early neurological findings and neurodevelopmental outcomes up to 24 months of age. Secondarily, this study aims to explore whether early aEEG and NIRS findings may help identify subgroups of newborns with mild HIE who are at higher risk for neurological deterioration and may benefit from closer monitoring and follow-up.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey (Türkiye)
      • Bursa, Turkey (Türkiye)
        • Recruiting
        • Bursa City Hospital
        • Contact:
        • Principal Investigator:
          • Bayram Ali Dorum, Associate professor
        • Sub-Investigator:
          • Erbu Yarcı, Associate professor
      • Bursa, Turkey (Türkiye)
        • Recruiting
        • Division of Neonatology, Department of Pediatrics, Bursa Uludağ University Faculty of Medicine
        • Contact:
        • Sub-Investigator:
          • Hilal Özkan, Professor
        • Sub-Investigator:
          • Cansu Sivrikaya Yıldırım, Neonatologist
        • Principal Investigator:
          • Salih Çağrı Çakır, Associate professor
        • Sub-Investigator:
          • Nilgün Köksal, Professor
        • Sub-Investigator:
          • Rabia Tütüncü Toker, Associate professor
        • Sub-Investigator:
          • Zeynep Yazıcı, Professor
        • Sub-Investigator:
          • Dilek Sağlam, Associate professor
      • Bursa, Turkey (Türkiye)
        • Recruiting
        • Division of Neonatology, Department of Pediatrics, University of Health Sciences Bursa Yuksek İhtisas Training and Research Hospital
        • Sub-Investigator:
          • Gaffari Tunç, Associate professor
        • Contact:
        • Principal Investigator:
          • İpek Güney Varal, Associate professor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of newborns with a gestational age of ≥ 36 0/7 weeks who are diagnosed with mild hypoxic-ischemic encephalopathy within the first 6 hours after birth. Eligible participants include newborns with evidence of an acute peripartum or intrapartum asphyxial event who meet blood gas and clinical criteria for hypoxic-ischemic injury but do not fulfill criteria for moderate or severe encephalopathy or for therapeutic hypothermia at enrollment. Newborns will be prospectively followed from birth up to 24 months of age to assess both short-term and long-term neurological outcomes.

Description

Inclusion Criteria:

  1. Gestational age and postnatal age:

    Gestational age ≥ 36 0/7 weeks and enrollment within the first 6 hours after birth.

  2. Blood gas criteria

    Umbilical cord or postnatal (≤ 1 hour of life) blood gas showing:

    1. pH ≤ 7.00 or base deficit ≥ 16 mmol/L

    2. OR, if pH is 7.01-7.15 or base deficit is 10-15.9 mmol/L, the presence of both:

      • An acute perinatal event, and
      • Apgar score ≤ 5 at 10 minutes or ongoing resuscitation at 10 minutes of life, including the need for positive pressure ventilation.

    ( Evidence of an acute peripartum and intrapartum asphyxia event, defined by at least one of the following: Uterine rupture, placental abruption, umbilical cord prolapse, rupture, tight nuchal cord, maternal hemorrhage, trauma, or cardiopulmonary arrest, vasa previa, category III fetal heart rate tracing, including having either a sinusoidal pattern or absent baseline variability plus recurrent late decelerations, recurrent variable decelerations, or bradycardia.)

  3. Clinical evidence of encephalopathy Findings consistent with Sarnat and Sarnat Stage 1 (mild) encephalopathy. Mild, moderate, or severe abnormalities may be present in at least one of the six categories (level of consciousness, spontaneous activity, posture, tone, primitive reflexes [suck and Moro], autonomic nervous system), provided that no more than two categories show moderate or severe findings.

Exclusion Criteria:

Newborns meeting any of the following criteria will be excluded from the study:

  1. Normal neurological examination Newborns with a completely normal neurological examination according to Sarnat and Sarnat staging.

  2. Moderate or severe encephalopathy within the first 6 hours of life

    1. Clinical findings consistent with moderate or severe encephalopathy during the first 6 hours after birth.
    2. Presence of clinical seizures.
    3. aEEG findings consistent with moderate or severe encephalopathy requiring therapeutic hypothermia.
    4. Evidence of electrographic seizure activity on aEEG monitoring.
  3. Sarnat and Sarnat criteria for moderate-severe encephalopathy Findings consistent with moderate or severe encephalopathy in three or more Sarnat categories, classified as moderate or severe hypoxic-ischemic encephalopathy.

  4. Contraindications to therapeutic hypothermia, including:

    • Evaluation occurring more than 6 hours after birth.
    • Gestational age < 36 weeks or birth weight < 2000 g.
    • Severe or extensive intracranial parenchymal hemorrhage.
    • Severe, life-threatening coagulopathy.
    • Intracerebral infarction.
    • Chromosomal abnormalities (e.g., trisomy 13 or 18) or major congenital anomalies involving multiple organ systems.
  5. Lack of parental informed consent
  6. Cyanotic congenital heart disease
  7. Metabolic encephalopathy Encephalopathy due to metabolic disorders not related to hypoxic-ischemic events.

  8. Other conditions associated with encephalopathy unrelated to acute hypoxia

    • Abnormal fetal growth.
    • Maternal infections.
    • Fetomaternal hemorrhage.
    • Severe neonatal sepsis.
    • Chronic placental lesions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neurological Outcomes in Neonates with Mild Hypoxic-ischemic Encephalopathy
Time Frame: at 18 and 24 months of age
The primary outcome measure is the report of neurological outcome in children diagnosed with mild hypoxic-ischemic encephalopathy. Neurological outcome will be measured using the Bayley Scales of Infant and Toddler Development (Bayley-III) at 18-24 months of age; a standard score below 85 in at least one of the cognitive, motor, or language domains will be defined as a neurologic disorder.
at 18 and 24 months of age

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation Between Early aEEG Background Patterns and Neurological Outcomes in Newborns With Mild Hypoxic-Ischemic Encephalopathy
Time Frame: aEEG: within the first 72 hours of life. Neurological outcomes: at 18 and 24 months of age, birth to 24 months of age.

This outcome measure evaluates the correlation between:

  1. Continuous amplitude-integrated electroencephalography (aEEG) monitoring will be used within the first 72 hours of life to measure the amplitude (µV) of cerebral electrical activity and to determine background patterns and sleep-wake cycling; and
  2. Neurological outcomes, measured by the Bayley Scales of Infant and Toddler Development (Bayley-III) in the cognitive, motor, and language domains at 18 and 24 months of age.
aEEG: within the first 72 hours of life. Neurological outcomes: at 18 and 24 months of age, birth to 24 months of age.
Correlation Between Early Cerebral NIRS Values and Neurological Outcomes in Newborns With Mild Hypoxic-Ischemic Encephalopathy
Time Frame: Cerebral NIRS: within the first 72 hours of life. Neurological outcomes: at 18 and 24 months of age, birth to 24 months of age.

This outcome measure evaluates the correlation between:

  1. Early cerebral NIRS values within the first 72 hours of life. Cerebral oxygenation (%) values at NIRS measurements in infants, first 6 h of life, first 24 h of life, between 24-48 h, 48-72 h.
  2. Neurological outcomes, measured by the Bayley Scales of Infant and Toddler Development (Bayley-III) in the cognitive, motor, and language domains at 18 and 24 months of age.
Cerebral NIRS: within the first 72 hours of life. Neurological outcomes: at 18 and 24 months of age, birth to 24 months of age.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Uludag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 10, 2026

Primary Completion (Estimated)

February 10, 2027

Study Completion (Estimated)

February 10, 2029

Study Registration Dates

First Submitted

January 8, 2026

First Submitted That Met QC Criteria

February 5, 2026

First Posted (Actual)

February 6, 2026

Study Record Updates

Last Update Posted (Actual)

May 1, 2026

Last Update Submitted That Met QC Criteria

April 27, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2025/903/17-24

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

I am not authorized to share patient data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypoxic-Ischemic Encephalopathy Mild

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe